Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Advil · 1 trial · 1 indication
Participants were instructed to select a product for use upon their pain episode and then call a toll-free number for an interview within 30 minutes of the selection decision. Participants who did not call were interviewed after 14 days for data collection. The primary endpoint was derived from 2 variables: 1) number of participants who selected Naproxen Sodium ER and reported expected duration of pain less than or equal to 12 hrs (A); 2) number of participants who selected Naproxen Sodium ER and report expected duration of pain greater than 12 hrs (B). The results was calculated as B/(A+B).
| Arm | Type | Description |
|---|---|---|
| Naproxen Sodium ER (BAYH6689) or Advil IR | EXPERIMENTAL | Eligible subjects were provided with 24 Advil immediate-release (IR) caplets containing 200 mg Ibuprofen and Naproxen Sodium extended release (ER) tablets containing 660 mg Naproxen Sodium. Upon a single incidence of pain, subjects were instructed to review both packages and choose one product to use. Subject were not offered any additional instructions for use beyond what is on the packages. |
| Name | Type | Description |
|---|---|---|
| Naproxen sodium ER (BAYH6689) | DRUG | Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain |
| Advil | DRUG | Commercially available Advil; oral caplet upon incidence of pain |
Inclusion Criteria: * At least 12 years of age * Report taking at least one dose of Over-the-counter (OTC) analgesic for pain in the past month * Able to read and understand English * Provide written informed consent (subjects 12-17 years of age provide written assent and/or parent or legal guardia...
Advil is used for the treatment of pain. It is a small molecule drug being developed by Bayer AG. The drug is currently in Phase 3 clinical development, and it is intended to provide relief from pain symptoms.
Advil is developed by Bayer AG, a company traded under the ticker symbol BAYRY. The drug is currently in Phase 3 clinical trials for the treatment of pain, and it is a small molecule medication.
Advil is in Phase 3 clinical development. It is an investigational drug for the treatment of pain, and it has completed one Phase 3 trial. The drug is not yet approved and is still undergoing clinical evaluation.
Advil has been studied in one clinical trial with the identifier NCT01383486. This trial, titled 'Self Selection Trial of Naproxen Sodium', was a Phase 3 study that has been completed. The trial enrolled 253 participants in the United States and involved healthy volunteers.
Advil is the brand name for the drug, and the clinical trial NCT01383486 studied naproxen sodium, which is the active ingredient. The trial was a self-selection study of naproxen sodium, indicating that Advil contains this active ingredient for pain relief.